Skip to content
Biotechnology, Finance Investment

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Cleo Diagnostics Limited ASX.COV 2 mins read

 

Highlights

  • CLEO has appointed U.S.-based Lindus Health to manage U.S. clinical trials for its revolutionary ovarian cancer blood test

  • Lindus Health is a leader in clinical trial management for the med-tech sector, with a strong record of timely and successful trial execution

  • CLEO's U.S. study will prospectively recruit up to 500 patients commencing next month and will verify the performance of CLEO's pre-surgical ovarian cancer test for FDA regulatory approval.

________

 

MELBOURNE, AUSTRALIA, 11 April 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

 

U.S. Ovarian Cancer Clinical Trials

As a part of CLEO’s U.S. market access program, the Company will partner with U.S.-based CRO, Lindus Health, appointing it to manage the successful execution of its ovarian cancer U.S. clinical trials. Lindus Health was chosen following a robust process to identify a partner with the proven experience, technology and high standards capable of delivering on CLEO’s objectives.

Lindus Health specialises in collaborating with med-tech companies to conduct clinical trials worldwide, leveraging their innovative patient recruitment and trial management technology platform to deliver efficient and timely outcomes.

Comprehensive U.S. patient data is essential for a successful regulatory application through the Food and Drug Administration (FDA). CLEO will leverage Lindus Health’s expertise to execute a cost-effective and rapid clinical study that will support its subsequent FDA 510(k) application.

The study will benchmark CLEO’s pre-surgical ovarian cancer triage test and provide the core data requirements for the FDA 510(k) application. Up to 500 U.S.-based patients will be recruited, with the trial scheduled over 10 months following ethic approvals and site engagement.

An Australian arm of the trial will also run concurrently and be managed directly by CLEO. This dual-arm strategy mitigates risk to the timelines due to patient recruitment, and will provide additional patient samples for kit verification following manufacture.

The study data will be published in the mainstream medical literature as a part of CLEO’s rigorous publication strategy.

 

Commenting on the partnership with Lindus Health, CLEO Chief Executive, Richard Allman, said:

“With the appointment of Lindus Health, our U.S. market access program is well underway to achieve our goal of obtaining regulatory approval for CLEO’s initial pre-surgical market in the U.S. for our ovarian cancer blood test.

CLEO is appointing high calibre partners that we believe will help us deliver our important ovarian cancer detection technology to improve the health outcomes for women.”

 


-ENDS-

 

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0600
office@cleodx.com

Elvis Jurcevic
Investor Relations
+614 08 268 271
ej@cleodx.com

 

 

More from this category

  • Biotechnology, Science
  • 23/05/2024
  • 07:49
Brandon Capital

Up to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+

23 May 2024 Melbourne: The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round. Companies pioneering innovative health technologies to enhance the lives of individuals affected by dementia and cognitive decline are set to receive up to $5 million per project in non-dilutive project funding, a substantial boost for their innovative solutions. Funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF), the program aims to support the development of novel approaches, spanning therapeutics, diagnostics, assistive and medical devices and digital health technologies, that will…

  • Finance Investment, Oil Mining Resources
  • 22/05/2024
  • 10:21
Rincon Resources Limited (ASX: RCR)

Rincon Resources Limited (ASX: RCR) – Over-Subscribed A$5.6m Raising to Expand West Arunta Exploration

Perth, Western Australia - ASX listed minerals explorer, Rincon Resources Limited (ASX: RCR) ("Rincon" or "the Company") is pleased to announce the successful completion of an over-subscribed capital raising of A$5.6 million. The funds were raised through the placement of 56,000,000 fully paid ordinary shares at a price of $0.10 per share. This capital injection will primarily fund the expansion of exploration activities at the Company’s promising West Arunta Project in Western Australia. The placement attracted significant interest from institutional, professional, and sophisticated investors, along with continued support from existing shareholders. The shares were issued at the 10-day Volume Weighted…

  • Contains:
  • Finance Investment, Oil Mining Resources
  • 22/05/2024
  • 10:06
Zenith Minerals Limited (ASX:ZNC)

Zenith Minerals Limited (ASX:ZNC) – RC & AIRCORE DRILLING COMMENCED TO TEST GOLD & NICKEL TARGETS

Press Release: Zenith Minerals Announces Commencement of RC & Aircore Drilling at Hayes Hill to Test Promising Gold and Nickel Targets Perth, Australia – May 22, 2024 – Zenith Minerals Limited (ASX: ZNC), an Australian-based minerals exploration company, is pleased to announce that Reverse Circulation (RC) and Aircore drilling has commenced at the Hayes Hill Project, strategically located in the highly mineralized Norseman – Widgiemooltha area of Western Australia. This new drilling campaign aims to explore significant gold and nickel targets recently identified within the project area. Exciting Gold Prospects Between Major Mining Districts The Hayes Hill Project, positioned between…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.